Cathepsin Inhibitors Market - A potentially promising treatment for COVID-19 patients

Global Cathepsin Inhibitors Market Analysis

Overview

Cathepsins are a family of lysosomal proteases that are found in all mammals and other creatures and play an important role in cellular protein turnover. Serine proteases, aspartic proteases, and cysteine proteases are all members of the cathepsin family. Cathepsins D and E belong to the aspartyl protease family. Cathepsins B, L, H, K, S, and O belong to the cysteine protease family. Serine protease is found in cathepsin G. There are presently no licensed cathepsin inhibitors in the market, but numerous research and innovation operations are underway to create new cathepsin inhibitors for the cure of different illnesses, including cancer, traumatic brain injury, Ebola virus, and others.

Get Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2306

Drivers

Several major competitors in the market are undertaking clinical studies to acquire permission for cathepsin inhibitors, which are currently in the development stage and are eligible to receive approval soon.

Merck Sharp & Dohme Corp.'s Odanacatib, also known as MK-0822, is now being tested in a Phase 2 clinical study. MK-0822 is a cathepsin K inhibitor that is being developed for the treatment of osteoporosis in postmenopausal women. As a result, the existence of innovative medicines in the pipeline is projected to boost growth of the global cathepsin inhibitors market substantially over the forecast period.

In the coming years, the rising rate of illnesses for which cathepsin inhibitors are being developed may increase demand for such innovative therapy options. Traumatic brain injury (TBI) is a leading cause of mortality and disability in the U.S., according to CDC statistics from 2017. TBIs account for over 30% of all injury-related fatalities. Every day, 153 individuals in the U.S. die as a result of TBI-related injuries.

Regional Insights

Due to the high frequency of diseases such as cancer, which would drive demand for innovative cancer treatment techniques such as cathepsin inhibitors in the region, the North American cathepsin inhibitors market is projected to keep a prominent position in the global cathepsin inhibitors market.

As per the National Cancer Institute, about 1,735,350 new instances of cancer will be diagnosed in the U.S. in 2018, with approximately 609,640 individuals dying from the disease.

Due to regular research and development initiatives by major players in the region for the creation of novel cathepsin inhibitors, the Europe cathepsin inhibitors market is likely to rise significantly over the forecast period. The Swiss pharmaceutical firm F. Hoffmann-La Roche AG is testing RO5459072, a cathepsin S inhibitor, on the immunological response to a gluten challenge.

Tailored Information as per niche requirement:

LIMITED TIME OFFER - Hurry Up!

Exclusive offer!!! Purchase the report at a discounted rate!!!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Buy Now with Discount for Premium Report 2021: https://www.coherentmarketinsights.com/promo/buynow/2306

Competitive Landscape

Major companies contributing in the global cathepsin inhibitors market are Merck Sharp & Dohme Corp., F. Hoffmann-La Roche AG, LEO Pharma, and Virobay Inc.

Table of Content

Global Cathepsin Inhibitors Market Research Report

Section 1: Global Cathepsin Inhibitors Industry Overview

Section 2:  Global Economic Impact on Cathepsin Inhibitors Industry

Section 3:  Global Market Competition by Industry Producers

Section 4:  Global Productions, Revenue (Value), according to Regions

Section 5:  Global Supplies (Production), Consumption, Export, Import, geographically

Section 6:  Global Productions, Revenue (Value), Price Trend, Product Type

Section 7:  Global Market Analysis, on the basis of Application

Section 8:  Cathepsin Inhibitors Market Pricing Analysis

Section 9:  Market Chain, Sourcing Strategy and Downstream Buyers

Section 10:  Strategies and key policies by Distributors/Suppliers/Traders

Section 11:  Key Marketing Strategy Analysis, by Market Vendors

Section 12:  Market Effect Factors Analysis

Section 13:  Global Cathepsin Inhibitors Market Forecast

Have a Look at Related Research Insights:

ANAPLASTIC ASTROCYTOMA TREATMENT MARKET ANALYSIS

ANGINA PECTORIS TREATMENT MARKET ANALYSIS

PHOSPHODIESTERASE ENZYME (PDE) INHIBITORS MARKET ANALYSIS

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837